HOME > TOP STORIES
TOP STORIES
-
REGULATORY Japan Regulators Upped Zolgensma Price after Novartis Complaints: Chuikyo Paper
May 13, 2020
-
REGULATORY Zolgensma to Get Japan’s Highest List Price 167 Million Yen, but Peak Sales Put at Just 4 Billion Yen
May 12, 2020
-
BUSINESS Amgen Boosting Repatha Supply System to Gear Up for Praluent Switches
May 11, 2020
-
BUSINESS Praluent Barred in Japan after Top Court Nixes Sanofi’s Patent Claim
May 8, 2020
-
REGULATORY Japan Approves Remdesivir as First Drug for COVID-19
May 8, 2020
-
REGULATORY Japan to Test Ivermectin for COVID-19: Prime Minister
May 7, 2020
-
BUSINESS Gilead Files Remdesivir for COVID-19 in Japan
May 4, 2020
-
REGULATORY Japan Likely to Take FDA’s Anticipated EUA as Cue for “Special” Remdesivir OK
May 1, 2020
-
BUSINESS Sanofi Japan to Ensure Drug Supplies, Employees’ Safety at the Same Time in COVID-19 Crisis: Chief
April 30, 2020
-
REGULATORY Japan Might Approve Gilead’s Remdesivir for COVID-19 in May
April 28, 2020
-
BUSINESS Novartis Japan Scraps Sales Offices to Boost Efficiency of Rep Activities
April 27, 2020
-
REGULATORY Japan Moving to Thwart Foreign Takeover of Drug, Medical Devices Makers
April 24, 2020
-
BUSINESS Gene Techno CEO Eyes Lucentis Biosimilar Launch in November 2021, Expects Share of “At Least 30%”
April 23, 2020
-
BUSINESS Japan Heading into Earnings Season amid Coronavirus Woes
April 22, 2020
-
BUSINESS Drug Makers Restricting Nafamostat Supplies as Hopes Grow for Its Repurposing for COVID-19
April 22, 2020
-
COMMENTARY Drug Rep Number Might Have Logged 5,000-Plus Decrease in 1 Year: Jiho Tally
April 22, 2020
-
BUSINESS Sawai Curbing Shipments for 2 More Drugs after Nichi-Iko’s Massive Recalls
April 21, 2020
-
BUSINESS Sumitomo Dainippon Chair Sees No Need for Further Consolidation among Japan Drug Makers
April 21, 2020
-
BUSINESS Some Drug Makers Rejuvenating Workforce by Boosting New Hires after Job Cuts: Jiho Survey
April 20, 2020
-
BUSINESS Big 3 Generic Makers to Discontinue Procaterol Tablets as API Procurement Stalls
April 17, 2020
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
